Baxdela (delafloxacin) for Injection
|
|
- Brent Perkins
- 5 years ago
- Views:
Transcription
1 Last Review Date: July 25th, 2018 Number: MG.MM.PH.53 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth the clinical evidence that the patient meets the criteria for the treatment or surgical procedure. Without this documentation and information, EmblemHealth will not be able to properly review the request for prior authorization. The clinical review criteria expressed below reflects how EmblemHealth determines whether certain services or supplies are medically necessary. EmblemHealth established the clinical review criteria based upon a review of currently available clinical information (including clinical outcome studies in the peer-reviewed published medical literature, regulatory status of the technology, evidence-based guidelines of public health and health research agencies, evidence-based guidelines and positions of leading national health professional organizations, views of physicians practicing in relevant clinical areas, and other relevant factors). EmblemHealth expressly reserves the right to revise these conclusions as clinical information changes, and welcomes further relevant information. Each benefit program defines which services are covered. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that this service or supply is covered and/or paid for by EmblemHealth, as some programs exclude coverage for services or supplies that EmblemHealth considers medically necessary. If there is a discrepancy between this guideline and a member's benefits program, the benefits program will govern. In addition, coverage may be mandated by applicable legal requirements of a state, the Federal Government or the Centers for Medicare & Medicaid Services (CMS) for Medicare and Medicaid members. All coding and web site links are accurate at time of publication. EmblemHealth Services Company LLC, ( EmblemHealth ) has adopted the herein policy in providing management, administrative and other services to HIP Health Plan of New York, HIP Insurance Company of New York, Group Health Incorporated and GHI HMO Select, related to health benefit plans offered by these entities. All of the aforementioned entities are affiliated companies under common control of EmblemHealth Inc. Definitions The fluoroquinolone Baxdela (delafloxacin) is approved for use in adults for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by designated susceptible bacteria. In order to reduce the development of drug-resistant bacteria and maintain the effectiveness of Baxdela, it should only be used to treat infections that are proven or strongly suspected to be caused by bacteria. Dosing Max Units (per dose and over time): ABSSSI: 600 billable units every day for 14 days Guideline Baxdela (delafloxacin) is considered medically necessary when the following criteria are met: Patient is 18 years of age or older; AND Patient has a diagnosis of acute bacterial skin and skin structure infection (ABSSSI); AND Current culture and sensitivity (C&S) report shows isolated pathogen is a gram-positive or gramnegative organism susceptible to delafloxacin, unless provider submits documentation that obtaining a C&S report is not possible
2 Page 2 of 6 Limitations/Exclusions Approval will be granted for 14 days Subsequent approvals will require a new authorization Applicable Procedure Codes C9462 J3490 Injection, delafloxacin, 1 mg Unclassified drugs Applicable Diagnosis Codes A46 Erysipelas A49.01 Methicillin susceptible Staphylococcus aureus infection, unspecified site A49.02 Methicillin resistant Staphylococcus aureus infection, unspecified site A49.1 Streptococcal infection, unspecified site H Abscess of right upper eyelid H Abscess of right lower eyelid H Abscess of eyelid right eye, unspecified eyelid H Abscess of left upper eyelid H Abscess of left lower eyelid H Abscess of eyelid left eye, unspecified eyelid H Abscess of eyelid unspecified eye, unspecified eyelid H Cellulitis of right orbit H Cellulitis of left orbit H Cellulitis of bilateral orbits H Cellulitis of unspecified orbits H60.00 Abscess of external ear, unspecified ear H60.01 Abscess or right external ear H60.02 Abscess of left external ear H60.03 Abscess of external ear, bilateral H60.10 Cellulitis of external ear, unspecified ear H60.11 Cellulitis of right external ear H60.12 Cellulitis of left external ear H60.13 Cellulitis of external ear, bilateral J34.0 Abscess, furuncle and carbuncle of nose K12.2 Cellulitis and abscess of mouth K61.0 Anal abscess K61.1 Rectal abscess K61.2 Anorectal abscess K61.3 Ischiorectal abscess K61.4 Intrasphincteric abscess L00 Staphylococcal scalded skin syndrome L01.00 Impetigo, unspecified L01.01 Non-bullous impetigo L01.02 Bockhart s impetigo L01.03 Bullous impetigo L01.09 Other impetigo L01.1 Impetiginization of other dermatoses
3 Page 3 of 6 L02.01 Cutaneous abscess of face L02.02 Furuncle of face L02.03 Carbuncle of face L02.11 Cutaneous abscess of neck L02.12 Furuncle of neck L02.13 Carbuncle of neck L Cutaneous abscess of abdominal wall L Cutaneous abscess of back [any part, except buttock] L Cutaneous abscess of chest wall L Cutaneous abscess of groin L Cutaneous abscess of perineum L Cutaneous abscess of umbilicus L Cutaneous abscess of trunk, unspecified L Furuncle of abdominal wall L Furuncle of back [any part, except buttock] L Furuncle of chest wall L Furuncle of groin L Furuncle of perineum L Furuncle of umbilicus L Furuncle of trunk, unspecified L Carbuncle of abdominal wall L Carbuncle of back [any part, except buttock] L Carbuncle of chest wall L Carbuncle of groin L Carbuncle of perineum L Carbuncle of umbilicus L Carbuncle of trunk, unspecified L02.31 Cutaneous abscess of buttock L02.32 Furuncle of buttock L02.33 Carbuncle of buttock L Cutaneous abscess of right axilla L Cutaneous abscess of left axilla L Cutaneous abscess of right upper limb L Cutaneous abscess of left upper limb L Cutaneous abscess of right lower limb L Cutaneous abscess of left lower limb L Cutaneous abscess of limb, unspecified L Furuncle of right axilla L Furuncle of left axilla L Furuncle of right upper limb L Furuncle of left upper limb L Furuncle of right lower limb L Furuncle of left lower limb L Furuncle of limb, unspecified L Carbuncle of right axilla L Carbuncle of left axilla L Carbuncle of right upper limb L Carbuncle of left upper limb L Carbuncle of right lower limb L Carbuncle of left lower limb
4 Page 4 of 6 L Carbuncle of limb, unspecified L Cutaneous abscess of right hand L Cutaneous abscess of left hand L Cutaneous abscess of unspecified hand L Furuncle of right hand L Furuncle of left hand L Furuncle of unspecified hand L Carbuncle of right hand L Carbuncle of left hand L Carbuncle of unspecified hand L Cutaneous abscess of right foot L Cutaneous abscess of left foot L Cutaneous abscess of unspecified foot L Furuncle of right foot L Furuncle of left foot L Furuncle of unspecified foot L Carbuncle of right foot L Carbuncle of left foot L Carbuncle of unspecified foot L Cutaneous abscess of head [any part except face] L Cutaneous abscess of other sites L Furuncle of head [any part except face] L Furuncle of other sites L Carbuncle of head [any part except face] L Carbuncle of other sites L02.91 Cutaneous abscess, unspecified L02.92 Furuncle, unspecified L02.93 Carbuncle, unspecified L Cellulitis of right finger L Cellulitis of left finger L Cellulitis of unspecified finger L Acute lymphangitis of right finger L Acute lymphangitis of left finger L Acute lymphangitis of unspecified finger L Cellulitis of right toe L Cellulitis of left toe L Cellulitis of unspecified toe L Acute lymphangitis of right toe L Acute lymphangitis of left toe L Acute lymphangitis of unspecified toe L Cellulitis of right axilla L Cellulitis of left axilla L Cellulitis of right upper limb L Cellulitis of left upper limb L Cellulitis of right lower limb L Cellulitis of left lower limb L Cellulitis of unspecified part of limb L Acute lymphangitis of right axilla L Acute lymphangitis of left axilla L Acute lymphangitis of right upper limb
5 Page 5 of 6 L Acute lymphangitis of left upper limb L Acute lymphangitis of right lower limb L Acute lymphangitis of left lower limb L Acute lymphangitis of unspecified part of limb L Cellulitis of face L Acute lymphangitis of face L Periorbital cellulitis L Cellulitis of neck L Acute lymphangitis of neck L Cellulitis of abdominal wall L Cellulitis of back [any part except buttock] L Cellulitis of chest wall L Cellulitis of groin L Cellulitis of perineum L Cellulitis of umbilicus L Cellulitis of buttock L Cellulitis of trunk, unspecified L Acute lymphangitis of abdominal wall L Acute lymphangitis of back [any part except buttock] L Acute lymphangitis of chest wall L Acute lymphangitis of groin L Acute lymphangitis of perineum L Acute lymphangitis of umbilicus L Acute lymphangitis of buttock L Acute lymphangitis of trunk, unspecified L Cellulitis of head [any part, except face] L Cellulitis of other sites L Acute lymphangitis of head [any part, except face] L Acute lymphangitis of other sites L03.90 Cellulitis, unspecified L03.91 Acute lymphangitis, unspecified L04.0 Acute lymphadenitis face, head and neck L04.1 Acute lymphadenitis of trunk L04.2 Acute lymphadenitis of upper limb L04.3 Acute lymphadenitis of lower limb L04.8 Acute lymphadenitis of other sites L04.9 Acute lymphadenitis, unspecified L05.01 Pilonidal cyst with abscess L05.02 Pilonidal sinus with abscess L05.91 Pilonidal cyst without abscess L05.92 Pilonidal sinus without abscess L08.0 Pyoderma L08.1 Erythrasma L08.81 Pyoderma vegetans L08.82 Omphalitis not of newborn L08.89 Other specified local infection of the skin and subcutaneous tissue L08.9 Local infection of the skin and subcutaneous tissue, unspecified N48.21 Abscess of corpus cavernosum and penis N48.22 Cellulitis of corpus cavernosum and penis N61.0 Mastitis without abscess
6 Page 6 of 6 N61.1 Abscess of the breast and nipple N76.4 Abscess of vulva References 1. Baxdela (delafloxacin) tablets [prescribing information]. Lincolnshire, IL: Melinta Therapeutics, Inc; June 2017.
Yescarta (axicabtagene ciloleucel)
Last Review Date: March 30, 2018 Effective Date: April 1, 2018 Number: MG.MM.PH.42 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider
More informationTopical Oxygen Wound Therapy (MEDICAID)
Topical Oxygen Wound Therapy (MEDICAID) Last Review Date: September 8, 2017 Number: MG.MM.DM.15C8v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or
More informationChelation Therapy Last Review Date: February 10, 2017 Number: MG.MM.ME.48C3 Medical Guideline Disclaimer Definition Guideline Limitations/Exclusions
Last Review Date: February 10, 2017 Number: MG.MM.ME.48C3 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationHome Pulse Oximetry for Infants and Children
Last Review Date: April 21, 2017 Number: MG.MM.DM.12aC2v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationIntrathecal Baclofen for CNS Spasticity
Intrathecal Baclofen for CNS Spasticity Last Review Date: October 13, 2017 Number: MG.MM.ME.31bC7 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary
More informationOutpatient Cardiac Rehabilitation
Last Review Date: May 12, 2017 Number: MG.MM.ME.26bC3v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationTherapeutic Shoes for Diabetics
Last Review Date: August 11, 2017 Number: MG.MM.DM.03bC8v2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationAutomatic External Defibrillators
Last Review Date: April 21, 2017 Number: MG.MM.DM.10dC3v4 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationBlepharoplasty. Definitions
Last Review Date: June 9, 2017 Number: MG.MM.SU.10eC5 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationBRAF Mutation Analysis
Last Review Date: October 13, 2017 Number: MG.MM.LA.38aC Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationBone Mineral Density Studies in Adult Populations
Bone Mineral Density Studies in Adult Populations Last Review Date: July 14, 2017 Number: MG.MM.RA10aC6 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician
More informationAbscess. A abscess is a localized collection of pus in the skin and may occur on any skin surface and be formed in any part of body.
Abscess A abscess is a localized collection of pus in the skin and may occur on any skin surface and be formed in any part of body. Ethyology Bacteria causing cutaneous abscesses are typically indigenous
More informationPolicy and Procedure. Department: Utilization Management. SNP, CHP, MetroPlus Gold, Goldcare I&II, Market Plus, Essential, HARP
Retired Date: Page 1 of 9 1. POLICY DESCRIPTION: BRCA 1&2 Genetic Testing 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy, Claim
More information1. Skin care: Cleansing, lubrication, debriding and administration of antimicrobial therapy.
Lymphedema Treatment Last Review Date: October 13, 2017 Number: MG.MM.ME.05aC9 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider
More informationTitle: Remicade Biosmiliar Step Therapy Division: Medical Management Department: Utilization Management
Retired Date: Page 1 of 5 1. POLICY DESCRIPTION: Step Therapy Requirement for Remicade (J1745); trial with biosimilar Inflectra (Q5103) or Renflexis (Q5104). 2. RESPONSIBLE PARTIES: Medical Management
More informationS t a p h i n f e c t i o g r o i n p i c t u r e s
S t a p h i n f e c t i o g r o i n p i c t u r e s When someone is under an infection either in any area of the body or in the groin to be specific, the lymph nodes will swell up. Lymph nodes are located
More informationENCR RECOMMENDATIONS
E N C R EUROPEAN NETWORK OF CANCER REGISTRIES (ENCR) ENCR RECOMMENDATIONS Non-Melanoma Skin Cancers Members of the Working Group: Dr T. Davies, East Anglian Cancer Registry, Cambridge, UK Mrs M. Page,
More informationSuprapubic abscess icd 10 code
Suprapubic abscess icd 10 code Bacteria, viruses, parasites and swallowed objects can all lead to abscesses. Skin abscesses are easy to detect. They are red, raised and painful. Abscesses inside your body
More informationAPPROPRIATE TESTING FOR CHILDREN WITH UPPER RESPIRATORY INFECTION (URI) HEDIS (Administrative) NCQA Accreditation
APPROPRIATE TESTING FOR CHILDREN WITH UPPER RESPIRATORY INFECTION (URI) APPLICATIONS OBJECTIVE Purpose of Measure: ELIGIBLE POPULATION Which members are included? STANDARD OF CARE NCQA ACCEPTED CODES DOCUMENTATION
More informationTonsillectomy/Adenoidectomy
Last Review Date: January 12, 2018 Number: MG.MM.SU.58C2 Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationSUPPLEMENTAL MATERIAL
SUPPLEMENTAL MATERIAL efigures efigure: Standardised differences between TNF-α inhibitor users and non-users before and after matching on fixed factors and propensity scores. etables etable 1: All diagnoses
More informationStaph Infections. including MRSA
Staph Infections including MRSA What is a Staph infection? STAPH Staphylococcus aureus, often referred to simply as staph, are bacteria commonly carried on the skin or in the nose of healthy people. SYMPTOMS
More informationStaph infection groin pictures
Staph infection groin pictures Search TheBody.com fills you in on the topic, staph infections on the groin, with a wealth of fact sheets, expert advice, community perspective, the latest news/research.
More informationPembrolizumab (Keytruda )
Last Review Date: March 14, 2017 Number: MG.MM.PH.10f Medical Guideline Disclaimer Property of EmblemHealth. All rights reserved. The treating physician or primary care provider must submit to EmblemHealth
More informationMEDICAL POLICY Benign Skin Lesion Removal
POLICY: PG0105 ORIGINAL EFFECTIVE: 01/15/07 LAST REVIEW: 07/10/18 MEDICAL POLICY Benign Skin Lesion Removal GUIDELINES This policy does not certify benefits or authorization of benefits, which is designated
More informationExcessive skin on the eyelids due to chronic blepharedema, which physically stretches the skin.
Retired Date: Page 1 of 10 1. POLICY DESCRIPTION: Guideline for Blepharoplasty 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy, Claim
More informationIcd 10 code for cellulitis elbow
Icd 10 code for cellulitis elbow The Borg System is 100 % Icd 10 code for cellulitis elbow Free, official coding info for 2018 ICD - 10 -CM L03.113 - includes detailed rules, notes, synonyms, ICD -9-CM
More informationPalmetto Medicare Policy Primer
Palmetto Medicare Policy Primer Medicare Jurisdiction (JM) NC, SC, WV & VA Application of Skin Substitutes LCD #L36466 Indications Presence of neuropathic diabetic foot ulcer(s) having failed to respond
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Thyrogen) Reference Number: CP.PHAR.95 Effective Date: 03.12 Last Review Date: 08.18 Line of Business: Medicaid, HIM-Medical Benefit Revision Log See Important Reminder at the end of
More informationCLINICAL MEDICATION POLICY
CLINICAL MEDICATION POLICY Policy Name: Opdivo (nivolumab) injection Policy Number: Approved By: Medical Management, Clinical Pharmacy Products: Highmark Health Options Application: All participating hospitals
More informationWound & Burn. Reimbursement & Coding Guide
Wound & Burn Reimbursement & Coding Guide Wound & Burn Reimbursement and Coding Guide MicroMatrix and Cytal devices facilitate the remodeling of functional, site-appropriate tissue. Comprised of ACell
More informationSerious Skin Infection in Children: Midland Region James Scarfe Public Health Analyst Toi Te Ora Public Health Service
Serious Skin Infection in Children: Midland Region 2001-2012 James Scarfe Public Health Analyst Toi Te Ora Public Health Service Brent Harvey Analyst Clinical & Systems HealthShare Limited Dr. Justin Wilde
More informationFDA Approved Indication(s) Firmagon is indicated for treatment of advanced prostate cancer.
Clinical Policy: (Firmagon) Reference Number: CP.PHAR.170 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationIncidence and recurrence of boils and abscesses within the first year:
Research Laura J Shallcross, Andrew C Hayward, Anne M Johnson and Irene Petersen Incidence and recurrence of boils and abscesses within the first year: a cohort study in UK primary care Abstract Background
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Nerlynx) Reference Number: CP.PHAR.365 Effective Date: 09.05.17 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationPimples and Boils!! Dr Nathan Harvey Anatomical Pathology, PathWest
Pimples and Boils!! Dr Nathan Harvey Anatomical Pathology, PathWest Overview & Learning Objectives Review the cardinal signs/symptoms of acute inflammation Review the histological features of acute inflammation
More informationIcd 10 code bilateral ankle swelling with pain
Icd 10 code bilateral ankle swelling with pain The Borg System is 100 % Icd 10 code bilateral ankle swelling with pain Pelvic/perineal pain : Ganglion impar blocks of the sacrococcygeal joint are considered
More informationClinical Policy: Trabectedin (Yondelis) Reference Number: CP.PHAR.204 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Yondelis) Reference Number: CP.PHAR.204 Effective Date: 05.01.16 Last Review Date: 02.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Famvir) Reference Number: HIM.PA.63 Effective Date: 12/14 Last Review Date: 08/17 Line of Business: Health Insurance Marketplace Revision Log See Important Reminder at the end of this
More informationTitle: Automatic External Defibrillators Division: Medical Management Department: Utilization Management
Retired Date: Page 1 of 7 1. POLICY DESCRIPTION: Automatic External Defibrillators 2. RESPONSIBLE PARTIES: Medical Management Administration, Utilization Management, Integrated Care Management, Pharmacy,
More informationModular Program Report
Disclaimer The following report(s) provides findings from an FDA initiated query using Sentinel. While Sentinel queries may be undertaken to assess potential medical product safety risks, they may also
More informationICD-10 diagnostic codes consistent with ORBACTIV (oritavancin) indication
ICD-10 diagnostic codes consistent with ORBACTIV (oritavancin) indication ICD-10-CM Diagnosis Codes Diagnosis INDICATION ORBACTIV (oritavancin) for injection is indicated for the treatment of adult patients
More informationSample page. Surgical. Cross Coder. Essential links from CPT codes to ICD-10-CM and HCPCS
Cross Coder 2018 Surgical Essential links from CPT codes to ICD-10-CM and HCPCS POWER UP YOUR CODING with Optum360, your trusted coding partner for 32 years. Visit optum360coding.com. Contents Introduction...
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kadcyla) Reference Number: CP.PHAR.229 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM-Medical Benefit, Medicaid Coding Implications Revision Log See
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xofluza) Reference Number: CP.PMN.185 Effective Date: 10.30.18 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Brigatinib (Alunbrig) Reference Number: CP.PHAR.342 Effective Date: 07.17.17 Last Review Date: 05.18 Line of Business: Commercial; Medicaid Revision Log See Important Reminder at the end
More informationReimbursement Guide. Physical Performance Testing For Balance Assessment. September 18 th, Copyright 2013 Sway Medical LLC
Reimbursement Guide Physical Performance Testing For Balance Assessment September 18 th, 2013 The enclosed reimbursement recommendations are based on information gathered from thirdparty sources and is
More informationSERIOUS SKIN INFECTIONS IN NEW ZEALAND CHILDREN
SERIOUS SKIN INFECTIONS IN NEW ZEALAND CHILDREN A thesis submitted for the degree of Master of Medical Sciences at the University of Otago, Wellington, New Zealand Cathryn O Sullivan 16 th October 2011
More informationInpatient ICD-9-CM Mapping to ICD-10 PCS Procedures Involving the Application of Integra Bilayer Wound Matrix
Inpatient ICD-9-CM Mapping to ICD-10 PCS Procedures Involving the Application of Integra Bilayer Wound Matrix Effective October 1, 2015, the Centers for & Medicaid Services (CMS) is implementing International
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07.01.16 Last Review Date 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationCoverage Guidelines: Oral Formula: Rhode Island Products
Coverage Guidelines: Oral Formula: Rhode Island Products Effective: August 9, 2017 Clinical Documentation and Prior Authorization Required Applies to: Coverage Guideline, No Prior Authorization Tufts Health
More informationInpatient ICD-9-CM Mapping to ICD-10 PCS Procedures Involving the Application of PriMatrix AG Antimicrobial Dermal Repair Scaffold
Inpatient ICD-9-CM Mapping to ICD-10 PCS Procedures Involving the Application of PriMatrix AG Antimicrobial Dermal Repair Scaffold Effective October 1, 2015, the Centers for & Medicaid Services (CMS) is
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Glumetza, Fortamet) Reference Number: CP.HNCA.72 Effective Date: 11.01.15 Last Review Date: 05.18 Line of Business: Commercial - HNCA Revision Log See Important Reminder at the end of
More informationClinical Policy: Buprenorphine-Naloxone (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: Last Review Date: 02.
Clinical Policy: (Bunavail, Suboxone, Zubsolv) Reference Number: CP.PMN.81 Effective Date: 09.01.17 Last Review Date: 02.18 Line of Business: Medicaid See Important Reminder at the end of this policy for
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Myobloc) Reference Number: CP.PHAR.233 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Commercial, Medicaid Coding Implications Revision Log See Important Reminder
More informationClinical Policy: Levetiracetam (Spritam) Reference Number: CP.CPA.156 Effective Date: Last Review Date: 11.18
Clinical Policy: (Spritam) Reference Number: CP.CPA.156 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Iressa) Reference Number: CP.PHAR.68 Effective Date: 11.16.16 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationIcd 10 dx code skin lesion of back
Icd 10 dx code skin lesion of back The Borg System is 100 % Icd 10 dx code skin lesion of back ICD-10-CM Codes; ; L00-L99 Diseases of the skin and subcutaneous tissue; ; L80-L99 Other disorders of the
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tagrisso) Reference Number: CP.PHAR.294 Effective Date: 12.01.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Dysport) Reference Number: CP.PHAR.230 Effective Date: 07.01.16 Last Review Date: 05.18 Line of Business: Commercial, HIM, Medicaid Coding Implications Revision Log See Important Reminder
More informationSurgical Care at the District Hospital. EMERGENCY & ESSENTIAL SURGICAL CARE
Surgical Care at the District Hospital 1 5 Basic Surgical Procedures Key Points 2 5.1 Wound Management Many important procedures can be performed under local anesthesia and do not require a surgical specialist
More informationClinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: Last Review Date: 02.
Clinical Policy: Clozapine orally disintegrating tablet (Fazaclo) Reference Number: CP.PMN.12 Effective Date: 08.01.15 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Lacosamide (Vimpat) Reference Number: CP.PMN.155 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Invega) Reference Number: CP. PMA.10.11.19 Effective Date: 10.06.16 Last Review Date: 04.18 Line of Business: CenpaticoMedicaid Revision Log See Important Reminder at the end of this
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Caprelsa) Reference Number: CP.PHAR.80 Effective Date: 10.01.11 Last Review Date: 02.18 Line of Business: Health Insurance Marketplace, Medicaid Revision Log See Important Reminder at
More informationTexas Prior Authorization Program Clinical Criteria
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Glumetza) Reference Number: CP.PMN.72 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationHIDRADENITIS SUPPURATIVA
Print Close Window Note: Large images and tables on this page may necessitate printing in landscape mode. Copyright 2004-2005 The McGraw-Hill Companies. All rights reserved. Fitzpatrick Color Atlas, 5e
More informationClinical Policy: Goserelin Acetate (Zoladex) Reference Number: CP.PHAR.171 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Zoladex) Reference Number: CP.PHAR.171 Effective Date: 10.01.16 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More information82330 CALCIUM; IONIZED. ICD-10 Codes that Support Medical Necessity. ICD-10 Code. Description. A15.0 Tuberculosis of lung
82330 CALCIUM; IONIZED ICD-10 Codes that Support Medical Necessity ICD-10 Code Description A15.0 Tuberculosis of lung A15.4 Tuberculosis of intrathoracic lymph nodes A15.5 Tuberculosis of larynx, trachea
More informationClinical Policy: Dabrafenib (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 07/16 Last Review Date: 07/17 Line of Business: Medicaid
Clinical Policy: (Tafinlar) Reference Number: CP.PHAR.239 Effective Date: 07/16 Last Review Date: 07/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationClinical Policy: IncobotulinumtoxinA (Xeomin) Reference Number: CP.PHAR.231
Clinical Policy: (Xeomin) Reference Number: CP.PHAR.231 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationClinical Policy: Pertuzumab (Perjeta) Reference Number: CP.PHAR.227 Effective Date: Last Review Date: Line of Business: HIM, Medicaid
Clinical Policy: (Perjeta) Reference Number: CP.PHAR.227 Effective Date: 06.01.16 Last Review Date: 05.18 Line of Business: HIM, Medicaid Coding Implications Revision Log See Important Reminder at the
More informationWound Management in Urgent Care
Wound Management in Urgent Care Brittany Busse Wound Management in Urgent Care Brittany Busse, MD Med 7 Urgent Care Folsom, CA, USA ISBN 978-3-319-27426-3 DOI 10.1007/978-3-319-27428-7 ISBN 978-3-319-27428-7
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Saphris) Reference Number: CP.PMN.15 Effective Date: 12.01.14 Last Review Date: 02.18 Line of Business: Commercial, Health Insurance Marketplace, Medicaid Revision Log See Important Reminder
More informationClinical Policy: Apremilast (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17
Clinical Policy: (Otezla) Reference Number: CP.PHAR.245 Effective Date: 08/16 Last Review Date 08/17 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Roflumilast (Daliresp) Reference Number: CP.PMN.46. Line of Business: Medicaid
Clinical Policy: (Daliresp) Reference Number: CP.PMN.46 Effective Date: 11/11 Last Review Date: 08/17 Line of Business: Medicaid See Important Reminder at the end of this policy for important regulatory
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Vorinostat (Zolinza) Reference Number: CP.PHAR.83 Effective Date: 10.01.18 Last Review Date: 07.13.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Zurampic) Reference Number: CP.CPA.174 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Medicaid Medi-Cal Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Lesinurad (Zurampic), Lesinurad/Allopurinol (Duzallo) Reference Number: CP.PMN.150 Effective Date: 11.16.16 Last Review Date: 08.18 Line of Business: Commercial, Medicaid See Important
More information(NATO STANAG 2122, CENTO STANAG 2122, SEATO STANAG 2122)
(NATO STANAG 2122, CENTO STANAG 2122, SEATO STANAG 2122) Bacteria Bacteria are microscopic, single-celled forms of plant life, containing no chlorophyll. They live on the skin, on the surface of the stratum
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Vraylar) Reference Number: CP.PMN.91 Effective Date: 11.16.16 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationDermACELL AWM Comprehensive Reimbursement Resource Guide. Prepared by Musculoskeletal Clinical Regulatory Advisers, LLC. Version 01/2018.
2018 Comprehensive Reimbursement Resource Guide Prepared by Musculoskeletal Clinical Regulatory Advisers, LLC. Version 01/2018. DermACELL AWM Disclaimer: This information is for educational/informational
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Sprycel) Reference Number: CP.PHAR.72 Effective Date: 07.01.18 Last Review Date: 05.18 Line of Business: Oregon Health Plan Revision Log See Important Reminder at the end of this policy
More informationMedical Necessity Guidelines: Reconstructive and Cosmetic Surgery
Medical Necessity Guidelines: Reconstructive and Cosmetic Surgery Effective: April 12, 2017 Clinical Documentation and Prior Authorization Coverage Guideline, No Prior Required Authorization Applies to:
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Trintellix) Reference Number: CP.PMN.65 Effective Date: 05.01.15 Last Review Date: 08.18 Line of Business: HIM, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Istodax) Reference Number: CP.PHAR.314 Effective Date: 01.01.17 Last Review Date: 11.18 Line of Business: Medicaid, HIM-Medical Benefit Coding Implications Revision Log See Important
More informationClinical Policy: Pralatrexate (Folotyn) Reference Number: CP.PHAR.313 Effective Date: Last Review Date: Line of Business: Medicaid
Clinical Policy: (Folotyn) Reference Number: CP.PHAR.313 Effective Date: 02.01.17 Last Review Date: 11.17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Fortamet, Glumetza) Reference Number: CP.PMN.72 Effective Date: 11.01.15 Last Review Date: 02.19 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end
More informationRevision Log. See Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Kuvan) Reference Number: CP. PHAR.43 Effective Date: 02.01.10 Last Review Date: 02.18 Line of Business: Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationClinical Policy: Milnacipran (Savella) Reference Number: CP.PPA.15. Line of Business: Medicaid
Clinical Policy: (Savella) Reference Number: CP.PPA.15 Effective Date: 08/12 Last Review Date: 05/17 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the end of this
More informationSupplementary Online Content
Supplementary Online Content Lee C-C, Lee M-tG, Chen Y-S. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Internal Medicine. Published online October 5, 2015.
More information13/10. Microbiology Bacterial Skin Infections Dr Hani Masaadeh Areej al-arqan
13/10 Microbiology Bacterial Skin Infections Dr Hani Masaadeh Areej al-arqan Salam soul, this is the first Microbiology lecture of this system given by Dr.hani masaadeh. I ll do my best to make it easy
More informationCoding Wars: The Coding and Documentation Weapons to Win the Battle
Coding Wars: The Coding and Documentation Weapons to Win the Battle Howard W. Rogers M.D., Ph.D. Advanced Dermatology Norwich, CT rogershoward@sbcglobal.net Do We Still Need to Learn Coding? Low Complexity
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Ibrance) Reference Number: CP.PHAR.125 Effective Date: 10.01.15 Last Review Date: 11.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Pellet (Testopel) Reference Number: CP.PHAR.354 Effective Date: 08.01.17 Last Review Date: 11.18 Line of Business: Medicaid Coding Implications Revision Log See Important Reminder at the
More information